Canaccord Maintains Buy Rating and $28 PT on AVEO Pharmaceuticals

Comments
Loading...
A report from Canaccord reiterates its Buy rating and $28 price target on AVEO Pharmaceuticals AVEO. The report states, “Ahead of a December 7 ODAC meeting to discuss the merits of the NDA for Pfizer's axitinib, a potential competitor to AVEO's tivozanib in advanced renal cell carcinoma (RCC), we maintain our BUY rating on AVEO.” AVEO closed Friday at $14.99.
RCC Logo
RCCReady Capital Corporation 5.75% Senior Notes due 2026
$24.590.57%

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score
Edge Rankings
Momentum-
Growth-
Quality-
Value-
Price Trend
Short
Medium
Long
Market News and Data brought to you by Benzinga APIs
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm

Posted In: